Targeted LNPs For Extrahepatic Delivery Market Report 2026

Targeted LNPs For Extrahepatic Delivery Market Overview

• Targeted LNPs For Extrahepatic Delivery market size has reached to $1.81 billion in 2025 • Expected to grow to $4.68 billion in 2030 at a compound annual growth rate (CAGR) of 20.9% • Growth Driver: Rising Adoption Of Personalized Medicine Fueling The Growth Of The Targeted Lipid Nanoparticles (LNPs) For Extrahepatic Delivery Market Due To Increasing Demand For Precision Drug Delivery • Market Trend: Advancing Targeted Lipid Nanoparticle Technologies For Precise Extrahepatic Delivery • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Targeted LNPs For Extrahepatic Delivery Market?

Targeted lipid nanoparticles for extrahepatic delivery are advanced nanotechnology-based delivery systems engineered to transport therapeutic molecules to tissues and organs outside the liver with high specificity. These systems use optimized lipid compositions and targeting strategies to enhance cellular uptake, improve biodistribution, and minimize unintended accumulation. They play a critical role in improving the efficacy and safety of modern therapeutics by enabling precise and controlled delivery beyond hepatic tissues. The main product types of targeted lipid nanoparticles for extrahepatic delivery include ionizable lipid-based lipid nanoparticles, cationic lipid-based lipid nanoparticles, polyethylene glycol-coated lipid nanoparticles, and other lipid nanoparticle formulations. Ionizable lipid-based lipid nanoparticles refer to lipid carriers that can change their charge in response to pH, improving cellular uptake and delivery efficiency of nucleic acids or therapeutic molecules. These nanoparticles are used across therapeutic areas including oncology, infectious diseases, genetic disorders, metabolic diseases, and other therapeutic areas. They are applied in gene therapy, messenger ribonucleic acid (mRNA) vaccines, small interfering ribonucleic acid (siRNA) delivery, protein delivery, and other applications, and are utilized by end users including pharmaceutical companies, biotechnology companies, academic and research institutes, and other end users.

What Is The Targeted LNPs For Extrahepatic Delivery Market Growth Forecast?

The targeted lnps for extrahepatic delivery market size is expected to see exponential growth in the next few years. It will grow to $4.68 billion in 2030 at a compound annual growth rate (CAGR) of 20.9%. The growth in the forecast period can be attributed to growing pipeline of RNA therapeutics, rising demand for tissue targeted delivery, expansion of precision drug delivery platforms, increasing oncology nanoparticle research, higher biotech delivery partnerships. Major trends in the forecast period include extrahepatic targeted LNP formulations, ligand directed nanoparticle delivery, tissue specific RNA delivery systems, advanced ionizable lipid designs, modular targeted nanocarrier platforms.

Global Targeted LNPs For Extrahepatic Delivery Market Segmentation

1) By Product Type: Ionizable Lipid-Based Lipid Nanoparticles; Cationic Lipid-Based Lipid Nanoparticles; Polyethylene Glycol-Coated Lipid Nanoparticles; Other Lipid Nanoparticle Formulations 2) By Therapeutic Area: Oncology; Infectious Diseases; Genetic Disorders; Metabolic Diseases; Other Therapeutic Area 3) By Application: Gene Therapy; Messenger Ribonucleic Acid Vaccines; Small Interfering Ribonucleic Acid Delivery; Protein Delivery; Other Application 4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Academic and Research Institutes; Other End-Users Subsegments: 1) By Ionizable Lipid-Based Lipid Nanoparticles: Single Chain Ionizable Lipids; Multi-Chain Ionizable Lipids; Functionalized Ionizable Lipids 2) By Cationic Lipid-Based Lipid Nanoparticles: Quaternary Ammonium Cationic Lipids; Permanent Cationic Lipids; Helper Lipids in Cationic Formulations 3) By Polyethylene Glycol-Coated Lipid Nanoparticles: Polyethylene Glycolylated Lipids with Different Chain Lengths; Polyethylene Glycol-Lipid Conjugates with Targeting Ligands; Polyethylene Glycolylated Lipid Combinations for Stability 4) By Other Lipid Nanoparticle Formulations: Sphingomyelin-Based Lipid Nanoparticles; Biodegradable Lipid Nanoparticles; Modular or Hybrid Lipid Nanoparticles; Stimulus-Responsive Lipid Nanoparticles

What Is The Driver Of The Targeted LNPs For Extrahepatic Delivery Market?

The rising demand for personalized medicine (PM) is expected to propel the growth of the targeted lipid nanoparticles (LNPs) for extrahepatic delivery market going forward. Personalized medicine (PM) refers to therapies tailored to an individual’s genetic profile, disease characteristics, or biomarkers to maximize treatment efficacy and minimize side effects. Advances in molecular diagnostics, biomarker identification, and precision-based drug development are accelerating the adoption of personalized therapies. Targeted lipid nanoparticles play a critical role in enabling personalized medicine by facilitating the precise delivery of therapeutic agents to specific tissues or cell types, including extrahepatic targets, thereby enhancing therapeutic effectiveness and safety. For instance, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the rising demand for the personalized medicine (PM) is driving the growth of the targeted lipid nanoparticles (LNPs) for extrahepatic delivery market.

Key Players In The Global Targeted LNPs For Extrahepatic Delivery Market

Major companies operating in the targeted lnps for extrahepatic delivery market are Pfizer Inc., Sanofi S.A., Merck KGaA, FUJIFILM Pharmaceuticals U.S.A. Inc., Evonik Industries AG, Recipharm, CordenPharma International GmbH, Ardena Nanomedicines, Arcturus Therapeutics Holdings Inc., BIOVECTRA Inc., Ascendia Pharmaceuticals Inc., ABITEC Corporation, Creative Biolabs, Genevant Sciences GmbH, Polymun Scientific Immunbiologische Forschung GmbH, ST Pharm, eTheRNA immunotherapies NV, NanoVation Therapeutics, DIANT Pharma, Curapath, Phosphorex Inc.

Global Targeted LNPs For Extrahepatic Delivery Market Trends and Insights

Major companies operating in the targeted lipid nanoparticles (LNPs) for extrahepatic delivery market are focusing on technological advancements in targeted LNP platforms, including DARPin-conjugated systems, to enhance selective delivery to immune and tissue-specific cells. DARPin-conjugated lipid nanoparticles refer to LNPs functionalized with Designed Ankyrin Repeat Proteins (DARPins), which are engineered binding proteins capable of highly specific interactions with selected cell surface receptors. This targeting capability allows for improved uptake by specific cell types, supporting extrahepatic applications such as immune cell modulation and tissue-specific gene delivery. For instance, in November 2025, Acuitas Therapeutics Inc., a Canada-based biotechnology company, introduced next-generation LNP technologies designed for extrahepatic targeting, including platforms aimed at T-lymphocyte delivery, mucous-penetrant formulations for airway epithelial cells, and a pre-formed vesicle manufacturing approach intended to improve scalability, cost efficiency, and storage stability. These advancements expand the potential applications of mRNA-LNP therapeutics beyond the liver and support broader use cases in gene editing, vaccines, and personalized medicine.

What Are Latest Mergers And Acquisitions In The Targeted LNPs For Extrahepatic Delivery Market?

In August 2025, AbbVie Inc., a US-based biopharmaceutical company, acquired Capstan Therapeutics Inc. for an undisclosed amount. Through this acquisition, Abbvie aims to advance in vivo targeted lipid nanoparticles (tLNPs) therapies and accelerate the development of ribonucleic acid (RNA)-based treatments for b cell–mediated autoimmune diseases. Capstan Therapeutics Inc. is a US-based clinical-stage biotechnology company pioneering in vivo CAR-T therapy through a proprietary targeted lipid nanoparticle (tLNP) platform (CellSeeker).

Regional Insights

North America was the largest region in the targeted lipid nanoparticles (LNPs) for extrahepatic delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Targeted LNPs For Extrahepatic Delivery Market?

The targeted lipid nanoparticles for the extrahepatic delivery market consist of revenues earned by entities by providing services such as enhanced cellular uptake, targeted delivery, and protection of cargo. The market value includes the value of related goods sold by the service provider or included within the service offering. The targeted lipid nanoparticles for the extrahepatic delivery market also include sales of lipid nanoparticle formulations, targeting ligands, and delivery system components. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Targeted LNPs For Extrahepatic Delivery Market Report 2026?

The targeted lnps for extrahepatic delivery market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the targeted lnps for extrahepatic delivery industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.